Labcorp — Feb 6, 2025 release

r of $1.10 billion vs $748.7 million • Announced 10 transactions and launched new innovative tests meeting significant unmet medical needs in key specialty areas in full year 2024 • Full-Year 2025 Guidance: ◦ Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4% ◦ Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8% ◦ Free Cash Flow of $1.10 billion to $1.25 billion; midpoint growth of 7.2% BURLINGTON, N.C., February 6, 2025 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter ended December 31, 2024, and provided 2025 guidance. “In 2024, Labcorp delivered exceptional results driven by both organic and inorganic growth,” said Adam Schechter, chairman and CEO of Labcorp. “We announced 10 transactions to further establish our position as a trusted partner to hospitals, health systems and regional/local laboratories. Additionally, we strengthened our presence in key high growth areas including oncology, women’s health, neurology and autoimmune disease. In 2025, we are positioned to deliver strong growth and margin expansion across both Diagnostics Laboratories and Biopharma Laboratory Services, while we improve health and improve lives of patients around the world.” 1 In the fourth quarter, Labcorp advanced its position as a partner of choice for hospitals, health systems and regional/local laboratories: • Complete